Tzi Shin Toh, Hans Xing Ding, Anis Nadhirah Khairul Anuar, Nurul Syuhada Zulhaimi, Jia Wei Hor, Yong Chiang Pang, Ing Xian Kong, Jannah Zulkefli, Yi Wen Tay, Lei Cheng Lit, Shen-Yang Lim, Ai Huey Tan
{"title":"Plasma LBP and sCD14 levels in Parkinson's disease with Asian <i>LRRK2</i> risk variants: Associations with systemic inflammation and clinical severity.","authors":"Tzi Shin Toh, Hans Xing Ding, Anis Nadhirah Khairul Anuar, Nurul Syuhada Zulhaimi, Jia Wei Hor, Yong Chiang Pang, Ing Xian Kong, Jannah Zulkefli, Yi Wen Tay, Lei Cheng Lit, Shen-Yang Lim, Ai Huey Tan","doi":"10.1177/1877718X261499246","DOIUrl":"https://doi.org/10.1177/1877718X261499246","url":null,"abstract":"<p><p><i>LRRK2</i> is implicated in the Parkinson's disease (PD) microbiome-gut-brain axis. We compared plasma lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14), markers of gut permeability and endotoxin exposure, in PD patients with/without <i>LRRK2</i> p.G2385R and/or p.R1628P and controls, and examined their associations with systemic inflammation and clinical severity. Neither marker differed between groups. Among PD patients, LBP correlated with higher IL-6, TNF-α, and worse motor function, while sCD14 correlated with higher IL-6, CCL5, and worse constipation, with no <i>LRRK2</i> risk variant-specific associations. Further prospective longitudinal studies are warranted to determine the clinical significance of these associations.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261499246"},"PeriodicalIF":5.9,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Quentin Damiens, Victor Mille, Justin Faure, Marie-Blanche Valnet-Rabier, Matthieu Bereau
{"title":"Reply to correspondence: Gastrointestinal determinants of levodopa response in Parkinson's disease: An integrated perspective.","authors":"Quentin Damiens, Victor Mille, Justin Faure, Marie-Blanche Valnet-Rabier, Matthieu Bereau","doi":"10.1177/1877718X261505673","DOIUrl":"10.1177/1877718X261505673","url":null,"abstract":"<p><p>levodopa pharmacokinetic variability in Parkinson's disease, and we agree that gastrointestinal determinants of treatment response extend beyond gastric emptying. However, our review was deliberately focused on gastroparesis, while explicitly acknowledging that levodopa is absorbed in the duodenum and proximal jejunum and that gastrointestinal dysfunction in Parkinson's disease may involve more generalized transit abnormalities, small intestinal bacterial overgrowth, and gut microbiota-related mechanisms. Importantly, prolonged small bowel transit alone does not establish the direction or magnitude of its effect on levodopa bioavailability, nor does current evidence demonstrate that intestinal dysmotility is a more direct or predominant determinant than delayed gastric emptying. Rather than opposing gastric and intestinal mechanisms, we propose that gastric emptying, small bowel motility, and other pharmacokinetic, pharmacodynamic, and disease-related factors should be viewed as sequential, interdependent, and patient-specific determinants of levodopa response. Integrated studies combining gastrointestinal transit assessment, levodopa pharmacokinetics, and motor outcomes are therefore warranted.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261505673"},"PeriodicalIF":5.9,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13768297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chiara Camastra, Carme Uribe, Angenelle Eve Rosal, Caitilin Chow, Mary Elizabeth Coulombe, Alex Murgoci, Andrea Quattrone, Antonio P Strafella
{"title":"SV2A PET imaging in Parkinson's disease and atypical parkinsonism: A systematic review of neuroimaging methodologies and regional findings.","authors":"Chiara Camastra, Carme Uribe, Angenelle Eve Rosal, Caitilin Chow, Mary Elizabeth Coulombe, Alex Murgoci, Andrea Quattrone, Antonio P Strafella","doi":"10.1177/1877718X261505655","DOIUrl":"10.1177/1877718X261505655","url":null,"abstract":"<p><p>BackgroundReduced presynaptic density, commonly referred to as synaptic loss, is an early and clinically relevant feature of parkinsonian disorders. The development of positron emission tomography (PET) radiotracers targeting synaptic vesicle glycoprotein 2A (SV2A) has enabled in vivo quantification of synaptic density.ObjectivesThis systematic review examines neuroimaging methodologies and regional SV2A PET findings in Parkinson's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA).MethodsA systematic search of PubMed, Scopus, and Web of Science was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines, including studies employing validated SV2A PET radiotracers to quantify synaptic density in parkinsonian populations. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. Substantial methodological heterogeneity precluded meta-analysis; findings were synthesized narratively.ResultsFourteen studies were included. In PD, the substantia nigra was the most affected region, with striatal involvement more prominent in advanced disease (>6 years duration). In PSP and CBD, synaptic loss was widespread, exceeded grey matter atrophy, and correlated with clinical severity and cognitive decline; longitudinal PSP data showed reductions of approximately 3-4% per year in frontal and caudate regions. In MSA, infratentorial involvement (cerebellum, pons, medulla) predominated, enabling diagnostic differentiation with high accuracy (AUC up to 0.99).ConclusionsSV2A PET reveals disease-specific patterns of reduced presynaptic availability, consistent with synaptic loss, across parkinsonian disorders, supporting its potential as a diagnostic and monitoring biomarker. Methodological harmonization and longitudinal multicenter studies are needed to establish clinical utility.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261505655"},"PeriodicalIF":5.9,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13744485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caroline C Swain, Vaibhavi V Peshattiwar, Dipesh Pokharel, Khoi Le, Isabel Kennedy, Julia Kalbus, Denise Barbut, Michael Zasloff, Thyagarajan Subramanian, Kala Venkiteswaran
{"title":"Squalamine prevents motor and non-motor symptoms in the paraquat and lectin rat model of the body-first subtype of Parkinson's disease.","authors":"Caroline C Swain, Vaibhavi V Peshattiwar, Dipesh Pokharel, Khoi Le, Isabel Kennedy, Julia Kalbus, Denise Barbut, Michael Zasloff, Thyagarajan Subramanian, Kala Venkiteswaran","doi":"10.1177/1877718X261499534","DOIUrl":"10.1177/1877718X261499534","url":null,"abstract":"<p><p>Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S<sup>129</sup>-α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S<sup>129</sup>-α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261499534"},"PeriodicalIF":5.9,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13743542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Madelyn Savage-Black, Jordanna S Sevitz, Nicole M Rogus-Pulia
{"title":"Impact and management of cognition on speech and swallow function in Parkinson's disease.","authors":"Madelyn Savage-Black, Jordanna S Sevitz, Nicole M Rogus-Pulia","doi":"10.1177/1877718X261444487","DOIUrl":"10.1177/1877718X261444487","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a multisystem neurodegenerative disorder involving motor and nonmotor symptoms. Cognitive impairment, dysarthria, and dysphagia are common during disease progression and are associated with reduced quality of life, loss of functional independence with activities of daily living, and increased morbidity and mortality. While cognitive impairment, dysarthria, and dysphagia are each well-described in PD, the extent to which cognition influences speech and swallowing function in this population requires further study. This narrative review aims to synthesize current evidence on how cognitive impairment intersects with dysarthria and dysphagia in PD. Relevant literature was identified through targeted database searches and citation tracking, emphasizing correlational and dual-task studies on cognition in relation to speech and swallowing outcomes. Although findings vary across tasks, cognitive domains, and disease severity, the literature collectively suggests that speech and swallowing draw on higher-level cortical processes, particularly attention and executive function, and that cognitive decline and increased cognitive load impact speech and swallowing performance in PD. The burden on the cognitive system is often under-recognized in the context of dysarthria and dysphagia management in PD. Further research that deeply explores the needs of individuals with PD and their care partners across the continuum of cognitive decline is necessary to inform person-centered care, as well as treatment approaches that cooperatively target cognition and speech/swallow function. Finally, future research addressing cognition in the early or even prodromal phase of PD may offer opportunities to increase cognitive reserve and mitigate cognitive decline.Plain language titleHow thinking affects talking and swallowing in Parkinson's disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"81-91"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148016048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New insights into synaptic vesicle dysfunction in Parkinson's disease.","authors":"Julita Chlebowicz, Violetta Ivanova, Jacqueline Burré","doi":"10.1177/1877718X261431203","DOIUrl":"10.1177/1877718X261431203","url":null,"abstract":"<p><p>Parkinson's disease (PD) is characterized by progressive motor and non-motor dysfunction arising from synaptic pathology that precedes neuronal loss. Synaptic dysfunction represents a central pathological mechanism in both familial and sporadic PD, with multiple PD-linked genes directly regulating synaptic vesicle (SV) trafficking. Here, we review recent studies linking SV dysfunction to PD pathology by examining how disease-linked proteins dysregulate distinct steps in the SV cycle and by exploring their cascading effects on synaptic physiology and circuit function. We highlight three critical pathogenic mechanisms: (1) impaired neurotransmitter import and storage, (2) disrupted SV pool organization, and (3) altered SV exocytosis and endocytosis. We also review recent studies investigating how presynaptic pathology triggers impairments in postsynaptic plasticity and circuit-level reorganization across brain regions. Together, these studies highlight that presynaptic SV dysfunction is a central mechanism in PD pathogenesis and therefore a promising target for developing therapeutic strategies aimed at reverting these early disease-driving synaptic changes.Plain language titleNew insights into synaptic vesicle dysfunction in Parkinson's disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"105-119"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147444154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson's disease.","authors":"Tom Foltynie, Sonia Gandhi, Camille Carroll","doi":"10.1177/1877718X261420002","DOIUrl":"10.1177/1877718X261420002","url":null,"abstract":"<p><p>The traditional approach of using double-blind, placebo controlled, parallel group trial designs has confirmed the efficacy of a large number of agents in relieving the symptoms of Parkinson's disease (PD) but has not, to date, led to the discovery of any disease-modifying treatments for PD. There are multiple potential reasons underlying the failure to find disease modifying approaches, which may in part relate to; inadequate understanding of PD pathophysiology and therefore inappropriate target selection; the possibility that even good candidate drugs may simply fail to reach and to ultimately engage with their putative targets at the required dose; and the significant heterogeneity of the disease both in terms of its pathophysiology and its motor and non-motor symptoms. PD also has some additional challenges that may be addressed by careful consideration of trial design. This includes; its generally slow rate of disease progression necessitating long follow-up times to identify evidence of disease slowing; lack of understanding regarding the optimal stage of disease that might be most amenable to intervention; as well as lack of consensus regarding which outcome measures best capture patient relevant disease progression, and which biomarkers might consistently and objectively provide the earliest indication of disease progression. In this review we will discuss these issues and potential approaches that may help in the evolution of clinical trial design and thus ultimately provide a pathway to increase the likelihood of successful identification of disease-modifying treatments for Parkinson's disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"30-40"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tabitha N Rodriguez, Richard J Smeyne, Michelle Smeyne
{"title":"Neurobiology of exercise in Parkinson's disease.","authors":"Tabitha N Rodriguez, Richard J Smeyne, Michelle Smeyne","doi":"10.1177/1877718X261452869","DOIUrl":"10.1177/1877718X261452869","url":null,"abstract":"<p><p>Epidemiological, preclinical, and clinical studies increasingly support exercise as a potent neuroprotective and disease-modifying intervention in Parkinson's disease (PD). Preclinical studies, including toxin- and α-synuclein-based models, using voluntary, forced, and skilled exercise paradigms demonstrate preservation of nigrostriatal dopaminergic neurons, improved motor function, and activation of convergent pathways. Protective processes include upregulation of neurotrophic factors (BDNF, GDNF, VEGF and Irisin), enhanced mitochondrial biogenesis and oxidative resilience, reduced neuroinflammation, improved basal ganglia synaptic plasticity and increased lysosomal functions. Additional emerging mechanisms underlying exercise-induced neuroprotection involve vascular remodeling, pathways regulating cellular oxygen and hypoxia, modulation of the gut microbiome, and epigenetic reprogramming. Importantly, clinical studies mirror these preclinical findings, demonstrating improvements in motor symptoms, balance, fitness, and quality of life, along with functionally positive changes in exercise-responsive biomarkers such as BDNF, irisin, and glutathione. Collectively, these highlight exercise as a robust, multifaceted therapeutic strategy with significant implications for PD prevention and management. This review synthesizes findings from the past 5 years across preclinical models and patient studies to define how exercise reduces PD risk, slows symptom progression, and engages biological pathways relevant to neuroprotection and restoration.Lay abstractExercise, as a consistent lifestyle habit, is beneficial to overall health with cardiovascular and cognitive benefits; and also supports a better quality of life throughout aging. Exercise has been demonstrated to reduce the risk of developing Parkinsons's Disease as well as to delay the symptoms of PD. In this review we will report recent (2020-2025) preclinical and clinical studies that examine the mechanisms underlying exercise's neuroprotective benefit related to PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"92-104"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Parkinson's disease and the concept of resilience, cognitive, and motor reserve.","authors":"Merle C Hoenig","doi":"10.1177/1877718X261444486","DOIUrl":"10.1177/1877718X261444486","url":null,"abstract":"<p><p>Parkinson's disease (PD) shows pronounced clinical heterogeneity, with individuals presenting differing cognitive and motor trajectories despite similar levels of neurodegeneration, in particular striatal dopamine terminal loss. This variability underscores the relevance of considering resilience mechanisms, particularly cognitive and motor reserve, that may support preserved function in the face of progressive pathology and neurodegeneration. Building on a previously proposed conceptual framework of resilience in PD, this review provides an updated and integrative synthesis of recent evidence, including longitudinal studies, neuroimaging findings, and emerging insights into lifestyle-related factors. The review further extends the existing framework by addressing current methodological challenges and outlining future directions for incorporating resilience into neuroimaging research, biological staging models, and personalized intervention strategies in PD. Together, this work emphasizes the growing importance of resilience research in PD and its potential to improve prognostic accuracy and inform more precise and individualized therapeutic approaches.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"41-49"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arnout Bruggeman, Roosmarijn E Vandenbroucke, Patrick Santens
{"title":"Rationale and current status of fecal microbiota transplantations for Parkinson's disease.","authors":"Arnout Bruggeman, Roosmarijn E Vandenbroucke, Patrick Santens","doi":"10.1177/1877718X261455608","DOIUrl":"10.1177/1877718X261455608","url":null,"abstract":"<p><p>Treating a neurological disorder through the gut may seem counterintuitive, yet multiple lines of evidence highlight the gut's important role in Parkinson's disease (PD). Prodromal gastrointestinal symptoms, the presence of aggregated α-synuclein in enteric neurons, increased intestinal inflammation, and impaired epithelial barrier integrity all point to gut-level involvement in PD pathophysiology. The gut microbiome, markedly altered in individuals with PD, may be a key driver of these changes. Fecal microbiota transplantation (FMT) is currently the most effective strategy for achieving broad and durable modifications of gut microbiota composition. However, FMT is a complex, multi-step procedure requiring stringent methodological control. Modulating gut bacteria has demonstrated therapeutic potential in preclinical models of PD, and recent clinical trials have begun evaluating FMT in patients, although outcomes have been variable. In this review, we examine potential explanations for these divergent results, with a particular focus on methodological differences across trials. We also outline future directions for optimizing FMT study design in PD and discuss how these insights may guide the development of next-generation microbiota-targeted therapies.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"17-29"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148317726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}